Abbisko tenosynovial giant cell tumour therapy gains fast track status
Abbisko Therapeutics has received fast track designation from the US FDA for pimicotinib to treat tenosynovial giant cell tumour (TGCT).
Abbisko Therapeutics has received fast track designation from the US FDA for pimicotinib to treat tenosynovial giant cell tumour (TGCT).
What's Your Reaction?
